SUMMARY
SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell responses against the spike domain can be used to measure vaccine immune response. Individuals with lymphoma have defects in humoral and cellular immunity that may compromise vaccine response. In this prospective observational study of 457 participants with lymphoma, 52% of participants vaccinated on treatment had undetectable anti-spike IgG antibodies compared to 9% who were not on treatment. Marked impairment was observed in those receiving anti- CD20 antibody within 12 months where 60% had undetectable antibodies compared to 11% on chemotherapy, which persisted despite three vaccine doses. Overall, 63% had positive T-cell responses irrespective of treatment. Individuals with indolent B-cell lymphoma have impaired antibody and cellular responses that were independent of treatment. The significant reduction and heterogeneity in immune responses in these individuals emphasise the urgent need for immune response monitoring and alternative prophylactic strategies to protect against COVID- 19.
Competing Interest Statement
SHL, NC, MJ, DJP, AO, AK, ARC, AHT, KL, DJ, BW, TW, ATB, KR, BS, CG, DA, JF, OB, JB, VM, ABAN, LR, TM, SF, PWMJ and DG declare no competing interests. CF receives consultancy fees from AstraZeneca and participates in an advisory board for AstraZeneca, MA receives research funding from Pfizer, GPC receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer, RL reports receiving speaker fees and honoraria from Janssen and AJD reports receiving research funding and honoraria from AstraZeneca and Janssen.
Funding Statement
The PROSECO study is funded by the Blood Cancer UK Vaccine Research Collaborative, which is led by Blood Cancer UK in partnership with Myeloma UK, Anthony Nolan and the British Society for Haematology (21009), and supported by Cancer Research UK Advanced Clinician Scientist Fellowship to SHL (A27179), the Cancer Research UK/NIHR Southampton Experimental Cancer Medicine Centre (A25141), the NIHR Southampton Clinical Research Facility (Southampton Research Biorepository) and NIHR Southampton Biomedical Research Centre. DG receives support from the NIHR Great Ormond Street Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the UK National Health Service Health Research Authority (North West-Liverpool Central Research Ethics Committee, IRAS 294739; 233768).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author.